**Abstract**

Dopaminergic neurotransmission is mediated by multiple dopamine receptors, D~1~ ～ D~5~. Dopamine D~3~ receptors are highly expressed in the cerebellum; however, their pathophysiological functions are not fully understood. We previously demonstrated that cerebellar D~3~ receptors modulate the incidence of extrapyramidal motor disorders (Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 50, 157, 2014). In the present study, we conducted microinjection study to clarify the role of cerebellar D~3~ receptors in modulating D~1~ agonist-induced oral dyskinesia and L-DOPA-induced dyskinesia in rats. In normal SD rats, the D~1~ agonist SKF-38393 dose-dependently elicited vacuous chewing movements (VCM), which was blocked by SCH-23390 (D~1~ antagonist) and haloperidol (antipsychotic drug). Microinjection of the preferential D~3~ agonist 7-OH-DPAT into lobe 9 of the cerebellum significantly inhibited SKF-38393-induced VCM. The inhibition of VCM by 7-OH-DPAT occurred in a dose-dependent manner and was blocked by simultaneous treatment with U-99194A (D~3~ antagonist). In the unilateral 6-OHDA lesioned hemiparkinsonian rat model, chronic L-DOPA treatment elicited intensive dyskinesia including axial, forelimb and orolingual dyskinesia. However, microinjection of 7-OH-DPAT into lobe 9 of the cerebellum failed to alleviate L-DOPA-induced dyskinesia. The present results illustrate the important role of cerebellar D~3~ receptors in modulating D~1~ receptor-mediated dyskinesia, implying that stimulation of cerebellar D~3~ receptors can ameliorate tardive dyskinesia in the treatment of schizophrenia.
